HOOKIPA Pharma (HOOK) pre-clinical data on alternating 2-vector cancer therapeutics published in Cell Reports Medicine

Go back to HOOKIPA Pharma (HOOK) pre-clinical data on alternating 2-vector cancer therapeutics published in Cell Reports Medicine

Pre-clinical data on HOOKIPA’s alternating 2-vector cancer therapeutics published in Cell Reports Medicine

March 4, 2021 7:00 AM EST

Alternating, intravenous administration of two replicating arenaviral vectors induce tumor-specific responses exceeding 50% of the circulating CD8 T cells2-vector approach resulted in tumor cures and long-term immunity against tumor rechallengePublication underscores the potential of HOOKIPAs engineered arenavirus platform as a new class of cancer immunotherapeutics, currently being evaluated in a Phase 1/2 clinical trial in HPV16+ cancers

NEW YORK and VIENNA, Austria, March 04, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its... More